Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
September 30, 2020 07:07 AM EDTUpdated October 1, 04:09 AM
Coronavirus

Covid-19 roundup: No­var­tis' Vas Narasimhan sees drugs as 'bridge' to vac­cines; Mod­er­na spot­lights el­der­ly re­spons­es in NE­JM

ENDPOINTS

No­var­tis may be stay­ing out of the vac­cine pack, but the Swiss phar­ma gi­ant in­sists that its drugs will still have a cru­cial role to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times